U.S. FTC Hits Delay In Approving Aussie CSL’s Buy Of Talecris
This article was originally published in PharmAsia News
Executive Summary
A delay by a U.S. agency is expected to add several months to Australia-based CSL's $3.1 billion acquisition of Talecris Biotherapeutics Holdings. The U.S. Federal Trade Commission has asked for more information about the merger of CSL, the second-largest supplier of blood-plasma products, and U.S.-based Talecris, maker of key treatments for autoimmune diseases. The FTC is supposed to respond within 30 days to merger plans, but a CSL spokeswoman said the review process is now expected to take longer, but before August and the anniversary of the acquisition proposal. The deal hinges on agency approval within 12 months of the offer, and if not met, requires a $75 million fee to the venture company owners of Talecris. (Click here for more